Bharat Biotech trial nod a turning point for paediatric Covid-19 vaccine

Bharat Biotech has already conducted trials on children 12 years and above

With Bharat Biotech’s inactivated virus-based Covid19 vaccine Covaxin now set for phase 2 and 3 clinical trials on children in the 2-12 years age group, the stage is set for a paediatric range to hit the market.
 
Experts believe this is a critical step to ensure break in transmission.
 
Apart from Covaxin, two more vaccine candidates would be available for paediatric use in India. Zydus Cadila’s ZyCoV-D has been tested on children above 12 years and on Monday the USFDA authorized use of Pfizer’s mRNA vaccine on kids as young as 12 years.
 
Bharat Biotech has already